+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06735664

Study of Zanubrutinib and Odronextamab Combination Therapy for Patients with Richters Transformation

Led by City of Hope Medical Center · Updated on 2026-09-16

23

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and side effects of combining zanubrutinib, a drug that blocks a protein called Bruton tyrosine kinase, with odronextamab, a special antibody that targets cancer cells, in treating patients with Richters transformation, a form of transformed chronic lymphocytic leukemia. This is a phase I trial aiming to study how well this combination is tolerated and how effectively it works against the disease. Participants receive odronextamab through intravenous infusions on specific days of treatment cycles, starting with more frequent doses in the first cycle and less frequent doses in subsequent cycles. Zanubrutinib is taken orally once or twice daily beginning in the second cycle. Treatment cycles last 21 days initially, then 28 days up to a maximum of 12 cycles, with the option to continue zanubrutinib afterward. Throughout the study, patients undergo various scans and biopsies to monitor disease status and treatment effects. During the trial, participants have regular imaging tests such as PET and CT scans, blood tests, and biopsies to track response and safety. Heart function is checked before treatment starts. After finishing treatment, patients are followed up at 4 and 12 weeks, then every six months for up to three years to observe overall response, progression-free survival, and other long-term outcomes. The study measures side effects during the first two cycles and monitors adverse events up to 28 days after treatment ends.

CONDITIONS

Brief Title

Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here